Ascendis Pharma AS Working Capital to Net Assets Ratio
Ascendis Pharma AS working capital to net assets ratio. Ascendis Pharma AS (ASND) has a Working Capital to Net Assets ratio of -0.9% as of March 2026. Working capital of $-4.43 Million (current assets of $1.12 Billion minus current liabilities of $1.13 Billion) is measured against net assets of $488.48 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Ascendis Pharma AS (2011–2025)
Working capital to net assets ratio of Ascendis Pharma AS from 2011 to 2025. This chart shows how Ascendis Pharma AS's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at -0.9%, reflecting working capital of $-4.43 Million against net assets of $488.48 Million USD. Explore Ascendis Pharma AS (ASND) long-term investment share to see how much of total assets are deployed in long-term investments.
Ascendis Pharma AS Working Capital to Net Assets Ratio by Year (2011–2025)
Ascendis Pharma AS working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Ascendis Pharma AS from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Ascendis Pharma AS.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -24.3% | $39.58 Million | $-162.75 Million | $1.11 Billion | $1.07 Billion | ▲ +120.4 pp |
| 2024 | -144.7% | $153.00 Million | $-105.71 Million | $1.06 Billion | $907.86 Million | ▼ -167.9 pp |
| 2023 | 23.2% | $-33.79 Million | $-145.70 Million | $702.72 Million | $736.51 Million | ▼ -55.3 pp |
| 2022 | 78.5% | $206.69 Million | $263.35 Million | $923.47 Million | $716.78 Million | ▼ -1.4 pp |
| 2021 | 79.8% | $705.53 Million | $883.63 Million | $805.89 Million | $100.36 Million | ▼ -2.1 pp |
| 2020 | 82.0% | $687.33 Million | $838.71 Million | $740.13 Million | $52.80 Million | ▼ -12.4 pp |
| 2019 | 94.3% | $563.18 Million | $597.11 Million | $611.17 Million | $47.99 Million | ▲ +3.6 pp |
| 2018 | 90.7% | $253.99 Million | $280.05 Million | $292.91 Million | $38.92 Million | ▼ -5.9 pp |
| 2017 | 96.6% | $180.87 Million | $187.21 Million | $204.63 Million | $23.77 Million | ▲ +0.1 pp |
| 2016 | 96.5% | $170.50 Million | $176.61 Million | $183.96 Million | $13.46 Million | ▲ +1.6 pp |
| 2015 | 94.9% | $114.21 Million | $120.33 Million | $125.65 Million | $11.45 Million | ▲ +6.9 pp |
| 2014 | 88.0% | $40.30 Million | $45.81 Million | $53.16 Million | $12.86 Million | ▲ +75.3 pp |
| 2013 | 12.7% | $800.00K | $6.30 Million | $21.20 Million | $20.40 Million | ▲ +215.3 pp |
| 2012 | -202.6% | $-3.15 Million | $1.56 Million | $20.70 Million | $23.85 Million | ▲ +1684.9 pp |
| 2011 | -1887.6% | $-4.40 Million | $233.00K | $17.97 Million | $22.37 Million | — |